Flash, thanks for the discussion. My point was: A collaborative IND approach with the FDA/CDER will result in a more targeted precision approach which may provide the foundations of other drug trials.
Yes we need better "Public/Investor Relations"....don't know whether the current firm is lacking or whether CM is holding tight reins on them.
The BOD is being compensated with stock and options....so. if they are staying loyal to the company that is a testament to their faith in its future. They all have day jobs. Sandra has recently seen increased compensation and must doing a yeoman's job of keeping track of the money and making the financial reporting.
Market Data 
Markets 
AI
